1. Selective Immunomodulation in MS

3. Introduction

4. MS: Potential for Multi-Cellular Autoimmune Pathogenesis

5. Genetic and Environmental Factors Contribute to the Development of MS

6. MS as a Result of Imbalanced Immune-Regulatory Networks

7. Therapeutic Approach 1: General Immunosuppression

8. Therapeutic Approach 2: Immunomodulation

9. Therapeutic Approach 3: Immune-Selective Intervention – Neutralization / Interference With Leukocyte Trafficking

10. Therapeutic Approach 4: Immune-Selective Intervention - Depletion

11. Depletion Strategies

12. Networks That Drive and Attenuate MS Pathophysiology

13. Immune Regulation Approaches

14. Defining IRT - The 3Rs

15. T & B Cell Dynamics

16. Maintenance Therapies vs IRTs

17. CLARITY Study: Efficacy of Cladribine in RRMS

18. CLARITY Study: Time to First Relapse and Progression

19. Efficacy of Alemtuzumab vs IFN-Beta as First-Line Treatment: Phase 3 Study

20. Cladribine Safety Profile

21. Alemtuzumab Safety Profile

22. Case Study IRT - PART 1 HSCT vs Alemtuzumab vs Cladribine

23. Case 1: Discussion

24. European Bone Marrow Transplantation (EBMT) Guidelines: HSCT Eligibility

25. Alemtuzumab: CARE-MS 5-Year Data

26. Alemtuzumab: CARE-MS 8-Year Data

27. Long-term Efficacy of Cladribine: CLARITY Extension Study

28. Cladribine: MS Patients With High Relapse Activity had Reduced Risk of EDSS Worsening

29. HSCT vs Continued DMT in Patients With RRMS

30. Long-Term Outcomes After HSCT in Patients With MS

31. Case Study IRT - PART 2 HSCT vs Alemtuzumab vs Cladribine

32. Cohort Study: Alemtuzumab vs Natalizumab

33. Cohort Study: Cladribine vs Natalizumab

34. Derisking Immunosuppression

35. Derisking Immunosuppression

36. Derisking Immunosuppression

37. Practical Implications of IRTs

38. Conclusion

39. Abbreviations

40. Abbreviations (cont)

41. Abbreviations (cont)

42. Abbreviations (cont)